The epithelium to mesenchyme transition is thought to play a fundamental role during embryonic development and tumor progression. Loss of cell ± cell adhesion and modi®cation of both cell morphology and gene expression are the main events associated with this transition. There is a large amount of evidence suggesting that growth factors can initiate these events. Yet, the connection from growth factor induction to changes in cell adhesion and morphology is largely unknown. To elucidate this connection, we have investigated the action of IGF-II on E-cadherin/b-catenin complex-mediated cell ± cell adhesion and on b-catenin/TCF-3 mediated gene expression. We can show that (1) IGF-II induces a rapid epithelium to mesenchymal transition; (2) IGF1R, the receptor for IGF-II, belongs to the same membrane complex as E-cadherin and b-catenin; (3) IGF-II induces a redistribution of b-catenin from the plasma membrane to the nucleus and an intracellular sequestration and degradation of E-cadherin; (4) IGF-II induces the transcription of b-catenin/TCF-3 target genes. Based on the given case of IGF-II and E-cadherin/b-catenin complex, this study reveals the backbone of a cascade connecting growth factor signaling with cell ± cell adhesion during EMT. Oncogene (2001) 20, 4942 ± 4950.
Introduction E-cadherin, b-catenin and insulin-like growth factor 2 (IGF-II) belong respectively to families of cell ± cell adhesion molecules, armadillo-containing proteins and growth factors. Members of these three families are expressed ubiquitously in mammalian cells. E-cadherin, b-catenin and IGF-II are involved in normal growth, development and implicated in numerous pathological states, including malignancy Behrens, 2000; Birchmeier and Behrens, 1994; Peifer and Polakis, 2000) .
E-cadherin belongs to a large superfamily of calcium-dependent adhesion molecules, each consisting of ®ve repetitive extracellular domains, a single membrane-spanning region and a highly conserved cytoplasmic region (Nollet et al., 2000; Yagi and Takeichi, 2000) . The adhesive function of E-cadherin depends on the extracellular domain, which generates a homophilic interaction, and the cytoplasmic domain, which is responsible for binding to the cytoskeleton via b-catenin or plakoglobin (for review see Aberle et al. (1996) ; Redies and Takeichi (1996) ). E-cadherin is involved not only in adhesion, but also in morphogenesis, particularly interconversions between mesenchyme and epithelium (epithelium to mesenchyme transition [EMT] and mesenchyme to epithelium transition [MET] ). EMT plays a central role during embryogenesis and in the process of carcinoma cell dispersion (Boyer et al., 2000) . Epithelium may be de®ned as a set of tightly attached and polarized cells and mesenchyme as a set of loosely attached and non-polarized cells. The molecular mechanisms regulating E-cadherin dynamics in response to extracellular factors during EMT are still largely unknown.
b-catenin belongs to the armadillo protein superfamily (Ozawa et al., 1989; Peifer and Wieschaus, 1990) . The tyrosine phosphorylation of this molecule regulates cadherin-mediated cell ± cell adhesion (Hoschuetzky et al., 1994; Matsuyoshi et al., 1992; Muller et al., 1999) . b-catenin is also involved in the Wntmediated signal transduction, via interactions with various signaling molecules in the cytoplasm (Miller et al., 1999) . Wnt signaling results in b-catenin stabilization by inhibiting the serine phosphorylation of b-catenin and inducing its relocation to the nucleus with the transcription factor TCF Rubinfeld et al., 1996) . Finally, the b-catenin/LEF complex induces the transcription of target genes, such as those encoding c-myc and cyclin D1 (Morin, 1999) . b-catenin may account for the signaling role of Ecadherin, but E-cadherin dynamics and b-catenin signaling do not seem to be directly coupled (Sanson et al., 1996) . IGF1R (insulin-like growth factor receptor 1) is a heterotetrameric (a 2 b 2 ), disul®de bonded, transmem-brane glycoprotein containing extracellular ligandbinding and intracellular tyrosine kinase domains. IGF1Rb subunit binds the cytoplasmic proteins involved in IGF signaling (Baserga and Morrione, 1999; Blakesley et al., 1999) . IGF1R mediates the growth-promoting eects of Insulin, IGF (Insulin-like growth factor) -I and -II. IGF1R is the main receptor for IGF-II in vitro and in vivo (Baker et al., 1993; Germain-Lee et al., 1992; Louvi et al., 1997) .
E-cadherin, b-catenin and IGF-1R each play major, apparently independent, roles in oncogenetic and embryogenetic processes Birchmeier et al., 1996; Morin, 1999) . A biochemical interaction between E-cadherin, b-catenin and IGF-1R was ®rst demonstrated in vitro in human mammary carcinoma cells overproducing IGF1R (Guvakova and Surmacz, 1997) . We therefore investigated the connection between E-cadherin, b-catenin and IGF-1R during EMT, a fundamental cellular event in oncogenetic and embryogenetic processes.
Results

E-cadherin/b-catenin and IGF1R form a supramolecular complex in various cell types
IGF1R, E-cadherin and b-catenin form an immunocomplex in a transfectant of MCF-7 human mammary carcinoma cell line overproducing IGF1R (Guvakova and Surmacz, 1997). We assessed the biological signi®cance of this complex by investigating interactions between IGF1R and the E-cadherin/b-catenin complex in the rat bladder carcinoma-derived NBT-II cell line, the murine embryonic stem (ES) cell lines producing or not producing E-cadherin, the mouse NIH3T3 ®broblast line and the original MCF-7 human mammary carcinoma cell line. We examined the complex containing IGF1R and E-cadherin in these cell lines by detecting the IGF1Rb subunit in Ecadherin immunoprecipitates and reciprocally, by detecting E-cadherin in IGF1R immunoprecipitates. Cells were lysed and equivalent amounts of extracted proteins were subjected to immunoprecipitations with E-cadherin or IGF1R antibodies. E-cadherin was present in IGF1R immunoprecipitates from all Ecadherin-producing cell lines including NBT-II and wild-type ES cells and, to a lesser extent, in immunoprecipitates from MCF-7 cells (Figure 1a and data not shown). It was absent from NIH3T3 and ES cells lacking E-cadherin ( Figure 1a and data not shown). Therefore, IGF1R and E-cadherin form an immunocomplex in various cell lines and in dierent species.
As b-catenin interacts directly with E-cadherin in adhesion complexes, we investigated the presence of bcatenin in the complex containing IGF1R and Ecadherin by detecting b-catenin in IGF1R immunoprecipitates from these various cell lines (Figure 1a and data not shown). b-catenin was present in IGF1R immunoprecipitates from all E-cadherin-producing cell lines including NBT-II and wild-type ES cells and, to a lesser extent, in immunoprecipitates from MCF-7 cells ( Figure 1a and data not shown). b-catenin was absent in IGF1R immunoprecipitates from NIH3T3 cells. Thus, b-catenin is a member of the complex including IGF1R and E-cadherin. The presence of IGF1R was detected in all cell lines after immunoprecipitation and Western blot using IGF1R antibodies. Similar results were obtained with a-catenin (data not shown). In conclusion, IGF1R, E-cadherin, a-catenin and bcatenin belong to the same immunocomplex in various cell lines of dierent species.
To identify more precisely the IGF1R/E-cadherin interaction domain in E-cadherin, we used a transgenic mouse expressing a gene encoding a mutant form of Ecadherin (H2Ecad) in which the extracellular domain of E-cadherin was replaced by the extracellular domain of the major histocompatibility complex (MHC) class 1 Lysates derived from wildtype (WT) and transgenic (Tg) mammary glands were subjected to immunoprecipitation with an anti-IGF1R (top) or an antiH2Kd (bottom) antibody. The co-precipitation of E-cadherin or IGF1R was detected by immunoblotting with an antibody recognizing the cytoplasmic domain of E-cadherin and anti-IGF1R antibody, respectively. The transgenic mammary glands produced a chimaeric E-cadherin protein composed of the extracellular domain of H2Kd and the transmembrane and cytoplasmic domains of E-cadherin. The arrowhead and the arrow ending in a dot correspond to wild-type E-cadherin (120 kDa) and transgenic E-cadherin (70 kDa), respectively, and the asterisk corresponds to a non-speci®c signal observed only in mammary gland extracts but not in cell extracts. The arrow corresponds to IGF1Rb (90 kDa) molecule H2Kd. This chimaeric protein was targeted to the mammary glands (Delmas et al., 1999) . The proteins interacting with IGF1R and H2Kd in vivo were immunoprecipitated from protein extracts from wild-type (WT) and transgenic (Tg) mammary glands. Wild-type (120 kDa) and chimaeric (70 kDa) Ecadherins were present in IGF1R immunoprecipitates from transgenic mammary glands (Figure 1b, top) . However, even though the amount of wild-type and chimaeric E-cadherins was shown to be similar (Delmas et al., 1999) , fewer H2Ecad than E-cadherin molecules were present in the IGF1R immunocomplex. This may suggest that the complex Ecad/IGF1R is more stable than the complex H2Ecad/IGF1R. Moreover, the IGF1Rb subunit was detected in H2Kd immunoprecipitates from transgenic, but not from wild-type, mammary glands (Figure 1b, bottom) , indicating that the cytoplasmic domain of E-cadherin is sucient for the formation of a complex containing E-cadherin and IGF1R.
Altogether, our results demonstrate that IGF1R, a growth factor receptor, and E-cadherin/b-catenin, a cell adhesion complex, belong to a supramolecular complex in ES cells or in epithelial cells in vitro and in vivo. This interaction probably involves the cytoplasmic domain of E-cadherin and the IGF1Rb subunit.
IGF-II induces EMT
The morphology of NBT-II, ES, MCF-7 and NIH3T3 cells was followed by optical microscopy in the presence or absence of IGF-II. Cells were serumstarved for 2 h before the addition or not of IGF-II for 3 and 18 h ( As expected, these changes were observed with ES and MCF-7 cells (data not shown) but were not observed with NIH3T3 ®broblasts, a mesenchyme cell model. The height of NBT-II cells was determined by confocal microscopy using E-cadherin and IGF1R antibodies as markers (Figure 2e ,f). Before IGF-II treatment, the mean height of NBT-II cells was 6.8 mm. After 3 h IGF-II treatment, the mean height of NBT-II cells was about 4 mm. Similar results were obtained after 18 h IGF-II treatment. We next analysed the cellular distribution of desmoplakin, an epithelial cell marker, and of vimentin, a mesenchymal cell marker. Under standard conditions of culture, desmoplakin immunoreactivity was found in a cortical punctate pattern, indicating the presence of numerous desmosomes ( Figure 2g ). After IGF-II treatment, cells displayed a cytoplasmic spotted pattern of desmoplakin immunoreactivity ( Figure 2h ). This demonstrated that cell dissociation had occurred. In the absence of IGF-II, a very limited number of cells expressed vimentin ( Figure 2i ). In contrast, in the presence of IGF-II, a large number of NBT-II cells expressed vimentin ( Figure 2j ). This demonstrates that after IGF-II induction, NBT-II cells reorganized their intermediate ®laments. From this series of experiments. IGF-II was shown to induce a series of cellular and molecular changes associated to a standard EMT.
To further investigate the interactions between Ecadherin and IGF1R, the localization of these two proteins was determined before and after IGF-II treatment of various cell lines. We determined the distributions of IGF1R and E-cadherin in various cell lines using laser scanning confocal microscopy in the presence or absence of IGF-II (Figure 3 ). In the absence of IGF-II, the IGF1Rb subunit was detected at the cell ± cell contacts of both NBT-II and ES cells (Figure 3a ,c,e). Ecadherin was detected mainly at the cell ± cell contacts in NBT-II and ES cells, but was absent from NIH3T3 ®broblast cells (Figure 3a ',c',e'). IGF1Rb and Ecadherin were co-localized in cell ± cell contacts in NBT-II and ES cells, as shown in the superimposed images (Figure 3a'',c'' ). In the presence of IGF-II, the IGF1Rb subunit was detected mainly in the cytoplasm of NIH3T3, NBT-II and ES cells (Figure 3b,d,f ). Ecadherin was detected both at cell ± cell contacts and in the cytoplasm of NBT-II and ES cells (Figure 3b',d') . The amount of E-cadherin increased in the cytoplasm and decreased at the cell ± cell contact. As expected, no E-cadherin was detected in NIH3T3 cells (Figure 3f' ). Under these conditions, EMT took about 3 h, indicating that E-cadherin was rapidly removed from the plasma membrane.
It has to be pointed out that the EMT induced by IGF-II was a reversible phenomenon. NBT-II cells switched back to an epithelial morphology 24 h after removing IGF-II, and E-cadherin was observed at the cell ± cell contacts (data not shown).
IGF-II induces redistribution of the components of the supramolecular complex from the plasma membrane to the cytoplasm and nucleus
In order to better understand how E-cadherin was redistributed, we monitored the kinetics of the cellular redistribution of E-cadherin and of the proteins associated with it. The distribution of IGF1R and of the classical partners of b-catenin, i.e. E-cadherin and TCF-3, was determined by confocal microscopy, in NBT-II cells before and after IGF-II exposure ( Figure  4 ). Before IGF-II treatment, IGF1R was present both at cell ± cell contacts and within the cytoplasm ( Figure  4a [t=0]), whereas most of E-cadherin (Figure 4a',b' [t=0])) and b-catenin (Figure 4b, c [t=0] ) were concentrated at cell ± cell contacts and TCF-3 was present mainly in the cytoplasm (Figure 4c' [t=0] ). IGF-II treatment induced the gradual redistribution of E-cadherin, IGF1R and b-catenin from the cell membrane to other cell compartments. After 120 min of IGF-II treatment, IGF1R was predominantly located in the cytoplasm (Figure 4a [t=120] ). Ecadherin immuno¯uorescence was detected at the cell membrane and in the cytoplasm of most cells. In the cytoplasm,¯uorescence was either diuse or punctate, with the¯uorescent dots concentrated around the nucleus (Figure 4a ',b' [t=120]). b-catenin was detected at the cell membrane, in the cytoplasm and in the nucleus (Figure 4b,c [t=120] ). The distribution of bcatenin, at the membrane and in the cytoplasm, was similar to that observed for E-cadherin (Figure 4b' [t=120]). TCF-3 was detected both in the cytoplasm and nucleus (Figure 4c' [t=120] ). After 180 min of IGF-II treatment, IGF1R remained predominantly in the cytoplasm (Figure 4a [t=180] ). E-cadherin was present mainly in the cytoplasm, detected as¯uorescent dots concentrated around the nucleus (Figure 4a',b' [t=180]). b-catenin and TCF-3 were mainly concentrated in the nucleus (Figure 4b,c,c' [t=180] ). Cells located at the periphery of the colonies responded faster to IGF-II than cells in the center of the colonies (data not shown). Thus, the kinetics of protein redistribution diered from one cell to another, but after 360 min of IGF-II treatment, all attached cells revealed an identical distribution of the studied proteins to that described above for 180 min of IGF-II treatment. After 18 h of IGF-II treatment, E-cadherin was mainly localized in the cytoplasm, detected as¯uorescent dots concentrated around the nucleus (Figure 5a,b) . It was noticed that the amount of E-cadherin signal decreased regularly with IGF-II incubation time. In conclusion, IGF-II induces the redistribution of b-catenin from the plasma membrane and the cytoplasm to the nucleus, the redistribution of TCF-3 from the cytoplasm to the nucleus and the redistribution of E-cadherin and IGF1R to the cytoplasm.
In order to investigate the internalization of the Ecadherin/b-catenin/IGF1R complex, two types of experiments were performed. Double immuno¯uores-cence experiments showed a co-localization of IGF1R and E-cadherin, E-cadherin and b-catenin, and ®nally Figure 3 Co-localization of E-cadherin and IGF1R at the cell ± cell contacts. NBT-II (a ± b''), ES (c ± d'') and NIH3T3 (e ± f'') cells were treated (+) or not treated (7) with 100 ng/ml IGF-II for 3 h. IGF1R (a ± f) and E-cadherin (a' ± f') were detected with the appropriate antibodies. These two proteins were found to be colocalized in cells that produced both proteins, in the superimposed optical section images (a'' ± f''). Scale bar represents 10 mm IGF1R and b-catenin (Figure 4 and data not shown). A series of coimmunoprecipation-immunoblot experiments showed that the E-cadherin/b-catenin/IGF1R complex was still observable after a 6 h IGF-II treatment (data not shown). These series of results suggest strongly that the three proteins are internalized as a complex in the cells.
IGF-II induces the sequestration and partial degradation of E-cadherin in the cytoplasm
EMT involves the loss of epithelial traits, so we next investigated the disappearance of E-cadherin from the plasma membrane. In this respect, the co-localization of E-cadherin and LAMP-1, a marker of late endosomes and lysosomes (Honing and Hunziker, 1995) , was determined upon IGF-II treatment. In the absence of IGF-II, E-cadherin was detected at the cell membrane ( Figure 5c ) and LAMP-1 staining was punctate and restricted to the cytoplasm (Figure 5c') . No co-localization of E-cadherin and LAMP-1 was ever observed in the absence of IGF-II (Figure 5c'') . After IGF-II treatment, the two markers were observed to be partially co-localized around the nucleus ( Figure  5d ± d'' ).
To determine whether E-cadherin had been redistributed from the plasma membrane, rather than newly synthesized, we performed the same experiment in the presence of an inhibitor of protein translation, cycloheximide. A similar pattern of co-localization of LAMP-1 with E-cadherin was observed (Figure 5e ± e''). This suggests that, upon IGF-II treatment, Ecadherin is redistributed from the plasma membrane to late endosomes and lysosomes in which it is sequestrated.
A monoclonal antibody directed against the cytoplasmic domain of E-cadherin was used to detect Ecadherin in immunoblots and to immunoprecipitate Ecadherin from NBT-II cells treated with IGF-II for 180 min. In addition to the expected 120 kDa band, several degradation products of about 100, 80 and 40 kDa, corresponding to the C-terminal portion of Ecadherin, were detected for cells treated for 180 min with IGF-II (Figure 5f ). The main degradation product was about 40 kDa in size. In conclusion, it appears that IGF-II may induce a clear but limited E-cadherin degradation.
IGF-II induces the expression of b-catenin-specific target genes
The epithelial to mesenchyme transition involves the implementation of a new genetic program. So, we analysed the speci®c activation of genes during EMT. IGF-II induced the removal of E-cadherin from the plasma membrane and the relocation of b-catenin and TCF-3 to the nucleus. We therefore investigated whether IGF-II also induced the expression of known b-catenin/TCF-3 target genes. The level of expression of the cyclin D1 (Ccnd1) and c-myc (Myc) genes is high in various cell lines overproducing b-catenin in the nucleus (Morin, 1999) . NBT-II cells were treated with 100 ng/ml IGF-II for 0, 180 and 360 min. The expression of Ccnd1 and Myc was assessed by semiquantitative RT ± PCR, using b-tubulin (Tubb) as an internal reference and untreated NBT-II cells as an external reference (Figure 6a ). Myc expression increased in response to IGF-II treatment whereas Ccnd1 expression was unaected. (Figure 6b ). Thus, under these conditions, IGF-II activates the target genes of the b-catenin pathway.
Discussion
We describe here a molecular cascade beginning with IGF-II induction, involving E-cadherin/b-catenin/ IGF1R complex internalization, slight E-cadherin degradation, b-catenin nuclear relocation, and resulting in TCF/b-catenin target gene induction. These molecular events correlate with an EMT and thus link growth factor signaling with cell ± cell adhesion at the molecular level.
Many proteins interact directly with b-catenin, either at the plasma membrane (cadherins, a-catenin, Epidermal Growth Factor receptor) or in the cytoplasm (Adenomatous Polyposis Coli [APC], axin, conductin, ubiquitin) and in the nucleus (TCF/LEF, CREB Binding Protein [CBP], Pontin52) (Bauer et al., 1998a; Greaves et al., 1999; Peifer and Polakis, 2000) . Far fewer proteins interact directly with E-cadherin. The extracellular domain of E-cadherin may interact with E-cadherin itself, internalin or with aEb7 integrin (Cepek et al., 1994) . The cytoplasmic domain of Ecadherin interacts with b-catenin, plakoglobin and p120ctn and receptor Protein Tyrosine Phosphatase (PTPm). IGF1R interacts with Insulin Receptor Substrate 1 (IRS-1) and src-homology 2/collagen a proteins (SHC), enabling IGF1R to form complexes with a large number of cytoplasmic proteins. This study shows that E-cadherin, b-catenin and IGF1R form part of a large supramolecular complex in various tissues and cell lines. Two-hybrid experiments did not show any direct interaction between E-cadherin and IGF1R or between IGF1R and b-catenin (data not shown). Therefore, IGF1R is probably linked to Ecadherin or b-catenin via one of the known or as yet unidenti®ed cytoplasmic molecules with which they interact. -cadherin (c,d,e) , the late endosomal and lysosomal marker LAMP-1 (c',d',e') and the co-localization of these two molecules before (c,c',c'') and after IGF-II treatment in the presence (e,e',e'') or absence (d,d',d '') of 10 mM cycloheximide (CHX) for 2 h (CHX). The merge images (c'',d'',e'') correspond to the superimposition of E-cadherin and LAMP-1 images. Scale bar represents 10 mm. (f) NBT-II cells were induced by incubation with 100 ng/ml IGF-II for 180 min. Cell lysates containing an equivalent amount of proteins were subjected to immunoprecipitation with an anti-E-cadherin antibody and E-cadherin was detected by immunoblotting with the same antibody, which recognizes the cytoplasmic domain of E-cadherin. The full-length Ecadherin (120 kDa, arrow) and the degradation products (arrowheads) of about 100, 80 and 40 kDa, corresponding to the Cterminal portion of E-cadherin were ®rst detected after 3 h of IGF-II treatment. Note that the amount of Triton soluble E-cadherin increased after IGF-II treatment, indicating that E-cadherin was slightly redistributed from the insoluble to the soluble pool. After a longer exposure or an overloading of material, the degradation products of E-cadherin were not observed in non-IGF-II-treated cells IGF-II stimulation leads to the endocytosis of IGF1R in clathrin-coated vesicles (Lin et al., 1998) . In MDCK cells, E-cadherin is continually taken in and recycled via a clathrin-mediated pathway (Bauer et al., 1998b; Le et al., 1999) . We found that upon IGF-II stimulation, E-cadherin and IGF1R were transported from the plasma membrane into the cytoplasm. Ecadherin could be detected in LAMP-1-positive lysosomes whereas IGF1R was distributed throughout the cytoplasm. In previous studies, in the presence of EGF or FGF, a down-regulation of E-cadherin at the cell ± cell contact was observed during EMT of NBT-II cells (Boyer et al., 1992; Shiozaki et al., 1995) . However, the E-cadherin cytoplasmic localization could not be detected, because these authors used antibodies directed against the extracellular domain of E-cadherin and the cells were not permeabilized (Boyer et al., 1992) . A large number of EMT inducers have been identi®ed, but the mechanism by which E-cadherin is down regulated is unclear (Boyer et al., 1992; Eger et al., 2000) . Here, we provide the description of a rapid and stable cytoplasmic pathway for E-cadherin sequestration and degradation, biological events involved in normal and pathological EMT, such as mesoderm formation during development and pro-metastatic cell emigration from primary tumors during tumor progression.
Classically, Wnt-1 is able to increase the amount of b-catenin-free pool and subsequently the amount of nuclear b-catenin. Wnt-1-triggered b-catenin relocation to the nucleus is followed with transcriptional activation of speci®c target genes. In the present study, IGF-II induced b-catenin relocation to the nucleus and target gene activation in the absence of Wnt proteins. After a 30 min IGF-II induction, we could observe that b-catenin was moving from a peripheral location to a punctate cytoplasmic location (Figure 4) . A similar observation was recently reported after induction of colorectal cell lines with IGF-I (Playford et al., 2000) . We believe that these authors did not observe the translocation of b-catenin to the nucleus mainly because the time of induction was too short in their experiments.
The increase of the free cytoplasmic pool of bcatenin and the subsequent relocation of b-catenin to the nucleus can stem from two distinct mechanisms: (i) from the release of b-catenin from E-cadherin after the cytoplasmic relocation of the IGF1R/Ecadherin/b-catenin and the subsequent cytoplasmic sequestration and degradation of E-cadherin originally located at the membrane; (ii) from the increase of free b-catenin stability in the cytoplasm by the selective increase of tyrosine phosphorylation and/or decrease of serine phosphorylation of b-catenin. In the presence of IGF-I, it was shown that the stability of b-catenin increased after tyrosine phosphorylation (AndreÂ et al., 1999; Morin, 1999; Playford et al., 2000) . In parallel, in the presence of Insulin or IGF-I, the increase of b-catenin stability is the consequence of the decrease of serine phosphorylation. This inhibition of b-catenin serine phosphorylation is explained by the inhibition of GSK3 after IGF-Imediated-Akt activation (Alessi et al., 1996; Cross et al., 1995) .
Although we have demonstrated the concomitant nuclear relocation of b-catenin and induction of bcatenin target genes with EMT, future work is required to identify other b-catenin/TCF target genes in this model system. The known targets of b-catenin/TCF, such as c-myc, cannot account for the acquisition and maintenance of a mesenchymal phenotype. It was recently reported (Eger et al., 2000) that the activation of the c-Fos protein in mammary epithelial cell lines induced a loss of epithelial polarity in 4 days. In these cells, a small fraction of b-catenin belonged to the cytoplasmic pool. After 14 days of induction of c-Fos, a loss of E-cadherin was observed and b-catenin was located in the cytoplasm and in the nucleus. In the nucleus, b-catenin colocalized with TCF-3. These results are similar to the one we presented in this article. Yet, it should be underlined that the reported eects were observed in 3 h with IGF-II in our study and in 14 days with c-Fos in the work of Eger et al. (2000) . The induction of TCF-3/b-catenin target genes by IGF-II is probably based on the formation of a supramolecular complex containing IGF1R and Ecadherin/b-catenin. In this model, E-cadherin transduces IGF signals, resulting in the relocation of bcatenin to the nucleus and target gene activation. During vertebrate development, the formation of the mesoderm corresponds to the ®rst EMT. We previously showed that IGF-II promoted mesoderm formation (Morali et al., 2000) and that the E-cadherin overproduction antagonized the eects of IGF-II on mesoderm formation, suggesting that E-cadherin is able to modulate the IGF-II signaling pathway (Morali et al., 2001, in preparation) .
In conclusion, the known morphogenetic speci®city of cadherin may be directly linked with the selective molecular interaction of a speci®c cadherin with a given growth factor receptor, modulating selectively the signaling pathway downstream of the given receptor. In turn, this selective interaction may be the molecular basis to the adjustment of cell ± cell adhesion with growth factor signaling.
Materials and methods
Cell culture and transfection
Mouse NIH3T3 ®broblasts and rat bladder carcinomaderived NBT-II cells were cultured at 378C, in a 5% CO 2 / 95% air atmosphere in DMEM, supplemented with 10% heat-inactivated fetal calf serum and 2 mM L-glutamine. Human mammary carcinoma-derived MCF-7 cells and mouse embryonic stem cells (D3) were cultured in conditions described elsewhere (Guvakova and Surmacz, 1997; Larue et al., 1996) .
Antibodies and reagents
The mouse monoclonal anti-human IGF-IR antibody (aIR-3) was used for immunoprecipitation. The anity-puri®ed rabbit polyclonal anti-mouse IGF-IRb subunit antibody (C-20) was used for immunostaining and immunoblotting experiments. The mouse monoclonal anti-human E-cadherin (Clone 36), anti-mouse b-catenin (Clone 14) and the mouse monoclonal anti-vimentin (RPN1102) antibodies were used for all applications. We thank W Hunziker and M Pasdar for the rabbit polyclonal anti-rat LAMP-1 antibody (LY1C6) (Honing and Hunziker, 1995) and the rabbit polyclonal antibody directed against desmoplakin I/II (Pasdar and Nelson, 1988) , respectively.
Immunoprecipitation and immunoblotting
All the following steps were performed at 48C. Cells were rapidly washed three times in PBS and lysed in HNIG buer (see Guvakova and Surmacz, 1997) . Two hundred mg of 4-day lactating mammary gland were homogenized by grinding in 200 ml of HNIG buer. Immunoprecipitation and immunoblotting for cadherin and b-catenin were performed as described elsewhere (Butz and Larue, 1995) . For the preparation of total cell lysates, cells were lysed with boiling 1% SDS, 10 mM Tris-HCl, pH 7.4. The lysates were sonicated for 30 s and centrifuged at 15 000 g for 5 min at room temperature.
Immunostaining
The various cell lines were cultured for 36 h on glass coverslips. Cells were rinsed six times in phosphate-buered saline (PBS) at 378C and starved for 2 h in serum-free medium before stimulation with IGF-II. Cells were washed three times with PBS, ®xed in 4% paraformaldehyde for 10 min and permeabilized in 0.2% Triton X-100 for 5 min. The IGF-IRb subunit and E-cadherin were detected by incubation with 10 mg/ml anti-IGF-IRb (C-20) and 35 mg/ml anti-E-cadherin (C36) antibodies respectively for 1 h, followed by incubation with 15 mg/ml secondary antibodies for 30 min. The cells were rapidly washed three times and mounted in Immu-mount (Shandon). Staining was then assessed using a laser scanning confocal microscope driven by Scanware software (Leica). Images were collected using the same settings for similar detections and were processed by setting identical thresholds using Adobe Photoshop 4.0, in order to facilitate semi-quantitative comparisons.
Semi-quantitative RT ± PCR analysis of gene expression
NBT-II cells were incubated in serum-free DMEM for 2 h. Then, IGF-II was added to the medium at a ®nal concentration of 100 ng/ml for 0, 180 or 360 min. Total RNA was extracted and 1 mg was used as a template for AMV reverse transcriptase. Semi-quantitative PCR was performed as previously described (Kandel et al., 1991) , using the primer pairs 5' TAG TGC TGC ATG AGG AGA CA 3' and 5' GGT TTG CCT CTT CTC CAC AG 3' for c-myc (myc), 5' TCT ACA CTG ACA ACT CTA TCC G 3' and 5' TAG CAG GAG AGG AAG TTG TTG G 3' for cyclin D1 (Ccdnl), 5' TCA CTG TGC CTG AAC TTA CC 3' and 5' GGA ACA TAG CCG TAA ACT GC 3' for b-tubulin (Tubb), producing fragments of 317, 303 and 318 bp, respectively. The amount of cDNA produced for each sample was determined using a Storm PhosphorImager to quantify the radioactive signal (Molecular Dynamics).
Reporter gene assays
Cells (2610 5 ) were seeded onto 35-mm tissue culture dishes. After 24-h incubation, they were transiently transfected using LipofectAMINE. Top-¯ash, Fop-¯ash or PGK-b galactosidase plasmids were used, 1 mg per 35 mm tissue culture dish (Aoki et al., 1999) . Five hours post-transfection, the cells were separated into two 35-mm dishes in complete medium. They were incubated for 33 h, washed with PBS, starved by incubation for 2 h in serum-free DMEM and then incubated for 16 h in serum-free DMEM with or without IGF-II. Cells were harvested and processed for determination of luciferase and b-galactosidase activity (Aoki et al., 1999) . Luciferase activity was normalized against b-galactosidase activity.
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